Literature DB >> 8061113

Enhanced expression of HLA-A,B,C and inducibility of TAP-1, TAP-2, and HLA-A,B,C by interferon-gamma in a multidrug-resistant small cell lung cancer line.

B Fisk1, C G Ioannides, S Aggarwal, J T Wharton, C A O'Brian, N Restifo, B S Glisson.   

Abstract

Recent evidence suggests that deficient HLA Class I expression in SCLC lines may be due, in part, to down-regulation of TAP-1 and TAP-2 expression, and, thus, deficient antigen processing. Given the capability of the multidrug transporter mediating MDR, P-gp, to transport peptides, we hypothesized that P-gp may substitute for TAP-1/TAP-2 and enhance antigen processing in SCLC. To investigate this, we studied the H69 line (parent SCLC) and VPR-2 (MDR subline selected in etoposide, P-gp +). HLA-A,B,C expression was significantly increased in VPR-2 cells relative to H69, and was much more inducible with IFN-gamma. TAP-1 and TAP-2 were expressed at low levels in both lines. Differential induction of TAP-1 expression with IFN-gamma exposure was observed, with a dramatic increase in VPR-2 cells, and no change in H69. TAP-2 expression was enhanced in both lines with IFN-gamma, but to a greater degree in VPR-2. VPR-2 cells were resistant to LAK killing relative to H69, and were minimally sensitized with IFN-gamma. In contrast, IFN-gamma enhanced susceptibility of H69 to LAK killing 3-fold. The direct correlation between enhancement of HLA-A,B,C expression by IFN-gamma and the differential inducibility of TAP-1 and TAP-2 expression in P-gp-SCLC lines is novel. Relative LAK sensitivity of H69 and its increase by IFN-gamma may have clinical implications.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8061113

Source DB:  PubMed          Journal:  Lymphokine Cytokine Res        ISSN: 1056-5477


  6 in total

1.  Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models.

Authors:  Denise L Crossland; Warren L Denning; Sonny Ang; Simon Olivares; Tiejuan Mi; Kirsten Switzer; Harjeet Singh; Helen Huls; Kate S Gold; Bonnie S Glisson; Laurence J Cooper; John V Heymach
Journal:  Oncogene       Date:  2018-04-06       Impact factor: 9.867

2.  Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein.

Authors:  V Karanikas; L A Hwang; J Pearson; C S Ong; V Apostolopoulos; H Vaughan; P X Xing; G Jamieson; G Pietersz; B Tait; R Broadbent; G Thynne; I F McKenzie
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

3.  A T-cell receptor associated with naturally occurring human tumor immunity.

Authors:  Bianca D Santomasso; Wendy K Roberts; Ashby Thomas; Travis Williams; Nathalie E Blachère; Mark E Dudley; Alan N Houghton; Jerome B Posner; Robert B Darnell
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-27       Impact factor: 11.205

4.  Targeting p53 as a general tumor antigen.

Authors:  M Theobald; J Biggs; D Dittmer; A J Levine; L A Sherman
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-19       Impact factor: 11.205

5.  Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.

Authors:  B Fisk; T L Blevins; J T Wharton; C G Ioannides
Journal:  J Exp Med       Date:  1995-06-01       Impact factor: 14.307

6.  Integrative genomics analysis of various omics data and networks identify risk genes and variants vulnerable to childhood-onset asthma.

Authors:  Xiuqing Ma; Peilan Wang; Guobing Xu; Fang Yu; Yunlong Ma
Journal:  BMC Med Genomics       Date:  2020-08-31       Impact factor: 3.063

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.